Market Overview

UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, Raises PT on Eli Lilly

Share:
Related LLY
Eli Lilly Gets FDA Expanded Indication For Type 2 Diabetes Treatment Synjardy To Add Treatment-Naïve Adults
BMO Analysts Say Merck's Fundamentals Don't Justify Its Valuations
Lilly, J&J, Novo Battle Diabetes -- And Each Other (Investor's Business Daily)

In a report published Wednesday, Bank of America Merrill Lynch reiterated its Buy rating on Eli Lilly & Co. (NYSE: LLY), and raised its price target from $46.00 to $52.00.

BofA Merrill Lynch noted, “Ramucirumab is a monoclonal antibody in development for multiple tumor types, with breast, lung and gastric being the furthest along in development (Phase III). Similar to Roche/Genentech's ~$6bn drug Avastin, ramu works by reducing tumors' access to blood supply. Ramu's specific mechanism of action is somewhat different, and based on pre-clinical and clinical data LLY believes that ramu could have some efficacy and/or tolerability advantages over Avastin. We are introducing preliminary sales estimates for ramu, with a launch in 2015 and sales ramping to a modest $500mn 5 years later.”

Eli Lilly & Co. closed on Tuesday at $44.71.

Latest Ratings for LLY

DateFirmActionFromTo
Jul 2016JefferiesMaintainsBuy
May 2016Leerink SwannMaintainsOutperform
May 2016Credit SuisseMaintainsOutperform

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill LynchAnalyst Color Price Target Analyst Ratings

 

Related Articles (LLY)

View Comments and Join the Discussion!